Insmed Inc Stock Current Valuation
| INSM Stock | USD 75.02 0.13 0.17% |
Valuation analysis of Insmed Inc helps investors to measure Insmed's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of the 9th of March 2025, Enterprise Value is likely to grow to about 10.2 B, though Enterprise Value Over EBITDA is likely to grow to (12.55). Fundamental drivers impacting Insmed's valuation include:
Fairly Valued
Today
Please note that Insmed's price fluctuation is very steady at this time. Calculation of the real value of Insmed Inc is based on 3 months time horizon. Increasing Insmed's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Insmed stock is determined by what a typical buyer is willing to pay for full or partial control of Insmed Inc. Since Insmed is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Insmed Stock. However, Insmed's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 75.02 | Real 75.45 | Target 88.14 | Hype 74.75 | Naive 75.67 |
The intrinsic value of Insmed's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Insmed's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Insmed Inc helps investors to forecast how Insmed stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Insmed more accurately as focusing exclusively on Insmed's fundamentals will not take into account other important factors: Insmed Inc Company Current Valuation Analysis
Insmed's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Insmed Current Valuation | 13.29 B |
Most of Insmed's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Insmed Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Insmed Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Insmed is extremely important. It helps to project a fair market value of Insmed Stock properly, considering its historical fundamentals such as Current Valuation. Since Insmed's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Insmed's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Insmed's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Insmed Inc has a Current Valuation of 13.29 B. This is 7.45% lower than that of the Biotechnology sector and 186.17% higher than that of the Health Care industry. The current valuation for all United States stocks is 20.03% higher than that of the company.
Insmed Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Insmed's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Insmed could also be used in its relative valuation, which is a method of valuing Insmed by comparing valuation metrics of similar companies.Insmed is currently under evaluation in current valuation category among its peers.
Insmed ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Insmed's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Insmed's managers, analysts, and investors.Environmental | Governance | Social |
Insmed Fundamentals
| Return On Equity | -8.91 | ||||
| Return On Asset | -0.29 | ||||
| Profit Margin | (2.51) % | ||||
| Operating Margin | (2.35) % | ||||
| Current Valuation | 13.29 B | ||||
| Shares Outstanding | 181 M | ||||
| Shares Owned By Insiders | 1.18 % | ||||
| Shares Owned By Institutions | 98.82 % | ||||
| Number Of Shares Shorted | 14.46 M | ||||
| Price To Earning | (8.70) X | ||||
| Price To Book | 47.58 X | ||||
| Price To Sales | 37.27 X | ||||
| Revenue | 363.71 M | ||||
| Gross Profit | 277.96 M | ||||
| EBITDA | (818.79 M) | ||||
| Net Income | (913.77 M) | ||||
| Cash And Equivalents | 554.87 M | ||||
| Cash Per Share | 4.62 X | ||||
| Total Debt | 45.49 M | ||||
| Current Ratio | 5.93 X | ||||
| Book Value Per Share | 1.59 X | ||||
| Cash Flow From Operations | (683.88 M) | ||||
| Short Ratio | 7.79 X | ||||
| Earnings Per Share | (5.57) X | ||||
| Target Price | 95.66 | ||||
| Number Of Employees | 1.27 K | ||||
| Beta | 1.28 | ||||
| Market Capitalization | 13.56 B | ||||
| Total Asset | 2.03 B | ||||
| Retained Earnings | (4.36 B) | ||||
| Working Capital | 1.32 B | ||||
| Current Asset | 28.15 M | ||||
| Current Liabilities | 3.89 M | ||||
| Net Asset | 2.03 B |
About Insmed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Insmed Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Insmed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Insmed Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Insmed Piotroski F Score and Insmed Altman Z Score analysis. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.57) | Revenue Per Share | Quarterly Revenue Growth 0.248 | Return On Assets | Return On Equity |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.